Abstract: Alzheimer’s disease and Down syndrome: Down syndrome (DS) is a genetic disorder caused by the presence of an extra complete or partial chromosome 21. Over the past few decades, significant advancements in medical treatment and nursing care have greatly improved the life expectancy of individuals with DS. However, as they age, their risk of developing Alzheimer’s disease (AD) increases considerably (Antonarakis et al., 2020). While DS patients experience multiple complications affecting various organs and systems due to developmental defects present from birth, AD remains a critical factor that significantly limits their lifespan. Consequently, delaying or even controlling the onset and progression of AD in DS is a crucial objective for potential drug development targeting this population.